Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
112 shown of 6,040 total abstracts
  1. Abstract 96722026-06-01 · 18:00 CT · S406
    Long-term follow-up of Imfinzi adjuvant for NSCLC: PACIFIC-64
    H. Rugo, M. Krop, F. Andre, et al. · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  2. Abstract 99062026-06-05 · 14:00 CT · S406
    Quality of life outcomes with Tagrisso in patients with NSCLC
    S. Peters, S. Tolaney · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  3. Abstract 94552026-06-02 · 18:15 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-354
    M. Krop, S. Antonia, C. Saura · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  4. Abstract 94582026-06-01 · 21:45 CT · E450
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-771
    H. Borghaei, S. Modi, J. Cortes, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  5. Abstract 98502026-06-05 · 18:30 CT · E450
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    S. Modi, A. Spira · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  6. Abstract 99402026-06-05 · 13:00 CT · S100A
    FLAURA-992: Tagrisso (osimertinib) neoadjuvant in NSCLC
    N. Rizvi, R. Herbst, S. Peters · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  7. Abstract 97182026-06-02 · 18:45 CT · S406
    IMpower-309: Tecentriq (atezolizumab) adjuvant in NSCLC
    J. Brahmer, M.C. Garassino, A. Spira, et al. · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  8. Abstract 92282026-06-03 · 16:30 CT · Hall B1
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    C. Robert, M. Krop · Peter MacCallum Cancer Centre
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  9. Abstract 94472026-06-05 · 14:45 CT · S100A
    Quality of life outcomes with Opdivo in patients with NSCLC
    J. Cortes, C. Saura, H. Borghaei, et al. · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  10. Abstract 99872026-06-01 · 20:15 CT · E450
    Long-term follow-up of Imfinzi 1L for SCLC: PACIFIC-457
    M.C. Garassino, S. Antonia, J. Brahmer · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  11. Abstract 91062026-06-02 · 14:15 CT · S406
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-590 study)
    S. Tolaney, R. Herbst, A. Spira, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  12. Abstract 95432026-06-05 · 14:30 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-113 study)
    G. Curigliano, S. Tolaney, M.C. Garassino · National Cancer Center Japan
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  13. Abstract 97592026-06-04 · 18:00 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-701
    R. Herbst, F. Andre, N. Rizvi, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  14. Abstract 99782026-06-01 · 13:00 CT · Hall B1
    Long-term follow-up of Tecentriq 2L for NSCLC: IMpower-432
    C. Robert, R. Herbst, G. Curigliano, et al. · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  15. Abstract 93232026-06-01 · 20:45 CT · E450
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-82
    G. Curigliano, P. Schmid · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  16. Abstract 91312026-06-04 · 20:45 CT · E450
    FLAURA-33: Tagrisso (osimertinib) 1L in NSCLC
    M. Krop, S. Antonia, P. Schmid, et al. · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  17. Abstract 99812026-06-02 · 14:00 CT · S406
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-5
    S. Antonia, J. Cortes · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  18. Abstract 94552026-06-04 · 16:15 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-842
    M.C. Garassino, S. Tolaney, R. Herbst, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  19. Abstract 98862026-06-03 · 19:00 CT · Hall B1
    Real-world effectiveness of Keytruda vs standard of care in NSCLC
    P. Schmid, C. Robert, L. Paz-Ares · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  20. Abstract 95922026-06-05 · 13:45 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-968
    S. Peters, C. Robert · Princess Margaret Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  21. Abstract 90852026-06-01 · 21:00 CT · E450
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-745
    G. Curigliano, L. Paz-Ares, S. Modi, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  22. Abstract 91202026-06-02 · 20:15 CT · Hall B1
    FLAURA-538: Tagrisso (osimertinib) 3L+ in NSCLC
    R. Herbst, M. Reck, M. Krop · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  23. Abstract 96662026-06-03 · 20:30 CT · E450
    Quality of life outcomes with Tecentriq in patients with NSCLC
    M.C. Garassino, H. Borghaei, R. Herbst · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  24. Abstract 90332026-06-01 · 19:00 CT · Arie Crown Theater
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    H. Rugo, C. Robert, J. Brahmer, et al. · University of Chicago
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  25. Abstract 97802026-06-03 · 19:15 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-434
    F. Andre, E. Winer · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  26. Abstract 91062026-06-04 · 13:45 CT · E450
    Long-term follow-up of Keytruda 1L for NSCLC: KEYNOTE-927
    G. Curigliano, L. Paz-Ares, E. Winer, et al. · National Cancer Center Japan
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  27. Abstract 96202026-06-04 · 16:00 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-1
    S. Modi, T. Mok · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  28. Abstract 95592026-06-01 · 21:30 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-200 study)
    M. Reck, S. Tolaney, L. Paz-Ares, et al. · Institut Gustave Roussy
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  29. Abstract 90412026-06-03 · 16:45 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-223 study)
    C. Robert, G. Curigliano, E. Winer, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  30. Abstract 99952026-06-04 · 19:15 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-120
    S. Peters, E. Winer, M. Krop, et al. · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  31. Abstract 92262026-06-05 · 18:15 CT · E450
    Long-term follow-up of Keytruda neoadjuvant for NSCLC: KEYNOTE-800
    C. Saura, C. Robert, S. Tolaney · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  32. Abstract 97142026-06-05 · 21:30 CT · S406
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-321
    M. Reck, H. Rugo, T. Mok, et al. · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  33. Abstract 94072026-06-03 · 15:45 CT · S406
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-998
    S. Tolaney, T. Mok, S. Modi · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  34. Abstract 90492026-06-05 · 16:15 CT · S406
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-928
    G. Curigliano, A. Spira, S. Peters · Institut Gustave Roussy
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  35. Abstract 91422026-06-05 · 14:15 CT · S100A
    Long-term follow-up of Keytruda 2L for NSCLC: KEYNOTE-944
    L. Paz-Ares, S. Tolaney, M. Krop · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  36. Abstract 97782026-06-05 · 15:30 CT · S406
    Quality of life outcomes with Imfinzi in patients with NSCLC
    J. Brahmer, A. Spira, C. Robert · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  37. Abstract 94282026-06-03 · 13:00 CT · S100A
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-712
    S. Antonia, S. Modi, J. Cortes, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  38. Abstract 90812026-06-05 · 16:45 CT · S406
    IMpower-467: Tecentriq (atezolizumab) adjuvant in NSCLC
    H. Borghaei, M.C. Garassino, E. Winer, et al. · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  39. Abstract 97002026-06-05 · 20:00 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-595
    C. Robert, L. Paz-Ares, E. Winer, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  40. Abstract 95612026-06-03 · 13:15 CT · S406
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-168
    T. Mok, N. Rizvi, J. Cortes, et al. · University of Chicago
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  41. Abstract 90162026-06-02 · 18:15 CT · S406
    Long-term follow-up of Imfinzi neoadjuvant for SCLC: PACIFIC-869
    N. Rizvi, S. Modi · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  42. Abstract 96522026-06-03 · 15:15 CT · S406
    Quality of life outcomes with Enhertu in patients with NSCLC
    M.C. Garassino, S. Peters, L. Paz-Ares, et al. · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  43. Abstract 97582026-06-02 · 19:30 CT · S100A
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-526
    H. Rugo, S. Modi · Institut Gustave Roussy
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  44. Abstract 97592026-06-04 · 20:00 CT · E450
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-767
    C. Saura, N. Rizvi, M.C. Garassino, et al. · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  45. Abstract 97642026-06-02 · 19:00 CT · S406
    Long-term follow-up of Imfinzi 2L for SCLC: PACIFIC-304
    S. Antonia, E. Winer, R. Herbst, et al. · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  46. Abstract 91002026-06-03 · 19:45 CT · Arie Crown Theater
    FLAURA-556: Tagrisso (osimertinib) 2L in NSCLC
    M. Reck, H. Borghaei, L. Paz-Ares, et al. · National Cancer Center Japan
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  47. Abstract 92332026-06-02 · 16:00 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-570
    G. Curigliano, S. Peters, J. Cortes, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  48. Abstract 95992026-06-04 · 19:15 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-151
    R. Herbst, N. Rizvi, G. Curigliano, et al. · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  49. Abstract 90292026-06-02 · 15:00 CT · S100A
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-74
    M.C. Garassino, S. Peters, J. Brahmer, et al. · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  50. Abstract 97142026-06-02 · 18:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-99 study)
    J. Cortes, F. Andre, M. Krop, et al. · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  51. Abstract 90092026-06-04 · 21:30 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-128
    L. Paz-Ares, S. Modi, P. Schmid, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  52. Abstract 97052026-06-01 · 18:30 CT · S100A
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-223
    C. Robert, J. Brahmer · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  53. Abstract 92492026-06-03 · 14:45 CT · E450
    Real-world effectiveness of Opdivo vs standard of care in NSCLC
    M. Krop, S. Peters, A. Spira, et al. · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  54. Abstract 91952026-06-02 · 15:00 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-389
    S. Modi, C. Robert, M. Reck, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  55. Abstract 96302026-06-02 · 15:15 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-287 study)
    F. Andre, A. Spira, H. Rugo, et al. · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  56. Abstract 91502026-06-03 · 13:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-381 study)
    T. Mok, R. Herbst · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  57. Abstract 98672026-06-02 · 15:30 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-881
    L. Paz-Ares, N. Rizvi, H. Borghaei · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  58. Abstract 93582026-06-05 · 18:00 CT · Arie Crown Theater
    PACIFIC-743: Imfinzi (durvalumab) 2L in SCLC
    J. Cortes, H. Rugo · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  59. Abstract 93562026-06-04 · 14:00 CT · E450
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-404
    S. Peters, L. Paz-Ares, M.C. Garassino, et al. · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  60. Abstract 94932026-06-04 · 13:15 CT · S406
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-564 study)
    F. Andre, S. Tolaney, H. Rugo, et al. · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  61. Abstract 93322026-06-05 · 20:00 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-514 study)
    S. Modi, T. Mok, H. Rugo, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  62. Abstract 92862026-06-01 · 13:45 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-446 study)
    G. Curigliano, C. Saura, S. Peters · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  63. Abstract 95042026-06-04 · 14:45 CT · Hall B1
    Real-world effectiveness of Imfinzi vs standard of care in NSCLC
    J. Brahmer, L. Paz-Ares, C. Saura, et al. · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  64. Abstract 97782026-06-01 · 21:45 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-982
    L. Paz-Ares, S. Antonia, M.C. Garassino, et al. · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  65. Abstract 98872026-06-04 · 14:45 CT · S406
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-337 study)
    J. Cortes, J. Brahmer, E. Winer, et al. · National Cancer Center Japan
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  66. Abstract 97062026-06-05 · 16:30 CT · E450
    Real-world effectiveness of Tecentriq vs standard of care in NSCLC
    S. Modi, C. Robert, C. Saura · Princess Margaret Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  67. Abstract 97882026-06-04 · 19:30 CT · S100A
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-311 study)
    L. Paz-Ares, J. Cortes · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  68. Abstract 95902026-06-01 · 21:00 CT · E450
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-408 study)
    T. Mok, N. Rizvi, S. Antonia · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  69. Abstract 94222026-06-05 · 18:30 CT · S100A
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-986
    L. Paz-Ares, J. Cortes, A. Spira, et al. · National Cancer Center Japan
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  70. Abstract 96332026-06-02 · 14:15 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-674
    L. Paz-Ares, H. Rugo · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  71. Abstract 95132026-06-04 · 19:45 CT · S406
    PACIFIC-69: Imfinzi (durvalumab) neoadjuvant in NSCLC
    M. Krop, J. Brahmer · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  72. Abstract 98102026-06-02 · 20:00 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-322 study)
    M. Krop, S. Modi · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  73. Abstract 93032026-06-05 · 14:30 CT · Hall B1
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-387
    S. Peters, S. Tolaney, R. Herbst · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  74. Abstract 97012026-06-04 · 19:30 CT · S406
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-762 study)
    J. Cortes, C. Saura · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  75. Abstract 95132026-06-05 · 18:45 CT · E450
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-840 study)
    E. Winer, A. Spira · Institut Gustave Roussy
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  76. Abstract 90932026-06-03 · 15:00 CT · E450
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-581 study)
    H. Borghaei, E. Winer, L. Paz-Ares, et al. · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  77. Abstract 99472026-06-05 · 14:00 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-368 study)
    M. Reck, P. Schmid, R. Herbst, et al. · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  78. Abstract 96842026-06-03 · 20:30 CT · S406
    Quality of life outcomes with Imfinzi in patients with SCLC
    E. Winer, S. Tolaney, A. Spira, et al. · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  79. Abstract 93402026-06-05 · 21:45 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-609
    J. Cortes, T. Mok · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  80. Abstract 98272026-06-03 · 15:45 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-740
    T. Mok, A. Spira, M. Krop · Institut Gustave Roussy
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  81. Abstract 94422026-06-01 · 21:00 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-758 study)
    E. Winer, C. Robert, M.C. Garassino · Institut Gustave Roussy
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  82. Abstract 96402026-06-03 · 20:00 CT · S100A
    FLAURA-249: Tagrisso (osimertinib) 1L in NSCLC
    P. Schmid, M.C. Garassino, M. Reck, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  83. Abstract 96182026-06-05 · 15:15 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-448
    F. Andre, R. Herbst, T. Mok, et al. · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  84. Abstract 95322026-06-03 · 15:30 CT · S406
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-939 study)
    R. Herbst, E. Winer, C. Robert, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  85. Abstract 92302026-06-02 · 20:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-152 study)
    R. Herbst, E. Winer · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  86. Abstract 96252026-06-02 · 19:30 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-314 study)
    F. Andre, N. Rizvi · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  87. Abstract 98712026-06-05 · 13:00 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-135 study)
    C. Saura, H. Borghaei, S. Modi · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  88. Abstract 94672026-06-02 · 20:00 CT · S100A
    Quality of life outcomes with Keytruda in patients with SCLC
    S. Modi, N. Rizvi, M. Krop, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  89. Abstract 98722026-06-02 · 16:30 CT · S406
    Long-term follow-up of Imfinzi 3L+ for SCLC: PACIFIC-501
    C. Saura, A. Spira, H. Rugo · Peter MacCallum Cancer Centre
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  90. Abstract 99422026-06-03 · 20:15 CT · S100A
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-816 study)
    M. Krop, T. Mok, J. Brahmer · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  91. Abstract 90852026-06-01 · 15:45 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-535
    G. Curigliano, M. Krop · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  92. Abstract 92472026-06-04 · 15:00 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-288
    L. Paz-Ares, A. Spira, G. Curigliano · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  93. Abstract 99112026-06-04 · 20:15 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 1L for NSCLC: KEYNOTE-660
    M. Krop, N. Rizvi, S. Tolaney · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  94. Abstract 93362026-06-01 · 15:00 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-924
    H. Rugo, N. Rizvi, T. Mok, et al. · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  95. Abstract 96692026-06-01 · 18:30 CT · E450
    Long-term follow-up of Keytruda neoadjuvant for NSCLC: KEYNOTE-969
    C. Robert, S. Tolaney, R. Herbst, et al. · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  96. Abstract 98642026-06-03 · 18:30 CT · S100A
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-21
    M. Krop, G. Curigliano, L. Paz-Ares, et al. · National Cancer Center Japan
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  97. Abstract 94802026-06-02 · 20:30 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-145
    A. Spira, R. Herbst, L. Paz-Ares · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  98. Abstract 94142026-06-05 · 18:45 CT · S100A
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-220 study)
    E. Winer, T. Mok, N. Rizvi · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  99. Abstract 91402026-06-03 · 13:30 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-539
    L. Paz-Ares, J. Cortes, T. Mok · University of Chicago
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  100. Abstract 97182026-06-04 · 13:45 CT · Arie Crown Theater
    Real-world effectiveness of Keytruda vs standard of care in SCLC
    S. Tolaney, P. Schmid · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  101. Abstract 90722026-06-05 · 13:15 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-127 study)
    P. Schmid, L. Paz-Ares, C. Robert, et al. · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  102. Abstract 99212026-06-05 · 16:30 CT · Arie Crown Theater
    DESTINY-Breast-680: Enhertu (trastuzumab deruxtecan) maintenance in NSCLC
    G. Curigliano, J. Brahmer, C. Robert, et al. · University of Chicago
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  103. Abstract 98702026-06-05 · 16:45 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-280 study)
    S. Modi, N. Rizvi · Institut Gustave Roussy
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  104. Abstract 92472026-06-04 · 16:15 CT · S100A
    IMpower-185: Tecentriq (atezolizumab) maintenance in NSCLC
    G. Curigliano, M. Krop, S. Antonia, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  105. Abstract 98912026-06-01 · 14:00 CT · S100A
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-929
    M.C. Garassino, P. Schmid, J. Brahmer, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  106. Abstract 95672026-06-01 · 16:00 CT · S406
    FLAURA-141: Tagrisso (osimertinib) 3L+ in NSCLC
    N. Rizvi, H. Borghaei · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  107. Abstract 94662026-06-04 · 21:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-329 study)
    J. Brahmer, M. Krop, R. Herbst · National Cancer Center Japan
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  108. Abstract 91122026-06-01 · 21:15 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-612 study)
    S. Peters, S. Modi, G. Curigliano · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  109. Abstract 94332026-06-04 · 20:15 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-726 study)
    E. Winer, M. Reck, H. Rugo, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  110. Abstract 99222026-06-02 · 20:00 CT · S406
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-23 study)
    R. Herbst, H. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  111. Abstract 99382026-06-05 · 19:00 CT · Hall B1
    FLAURA-912: Tagrisso (osimertinib) 3L+ in NSCLC
    E. Winer, P. Schmid, C. Saura, et al. · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  112. Abstract 90462026-06-04 · 16:45 CT · S406
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-874 study)
    T. Mok, P. Schmid · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.